Myocarditis Causing Premature Ventricular Contractions:Insights From the MAVERIC Registry
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorKansas City Heart Rhythm Research Foundation
About this trial
To assess potential link between unrecognized myocardial inflammation (myocarditis) and premature ventricular contractions (PVCs) associated with and without reduced Left ventricular ejection fraction (LVEF) through comprehensive diagnostic work up.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients > 18 years of age with mono-morphic or polymorphic PVC burden of ≥5000 in 24 hours.
Non-sustained VT was defined as ≥3 more consecutive beats lasting <30 seconds
Disqualifiers
History of myocardial infarction,
Significant flow-limiting coronary artery disease (≥50% stenosis) on invasive coronary angiography or CT angiography,
History of revascularization,
Significant symptomatic atrial arrhythmias associated with LV dysfunction,
Trial population
Males and females with PVC and ventricular tachycardia (VT) will be enrolled if they meet the inclusion/exclusion criteria
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Identify the underlying myocarditis in patients presenting with PVCs with or without reduced LVEF
To identify the underlying myocarditis in patients presenting with PVCs with or without reduced LVEF through laboratory testing, FDG-PET(18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose - positron emission tomography) scan, Cardiac Magnetic Resonance imaging and/or Endomyocardial biopsy.
Time frame
Retrospective Collection between dates January 2014-January 2023Secondary outcomes
1
Ascertain whether immunosuppressive therapy (IST) affords short term and long term improvement of LVEF and clinical outcomes
To ascertain whether immunosuppressive therapy (IST) affords short term and long term improvement of LVEF and clinical outcomes in virus negative and FDG-PET positive patients with non-ischemic cardiomyopathy, myocardial inflammation and PVCs.
Time frame
Retrospective Collection between dates January 2014-January 2023Other outcomes
1
Evaluate whether IST + catheter ablation results in optimal clinical response
To evaluate whether IST + catheter ablation results in optimal clinical response in virus negative and FDG-PET positive patients with PVCs with or without reduced LVEF
Time frame
Retrospective Collection between dates January 2014-January 2023Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Kansas City Heart Rhythm Research Foundation
Lead sponsor
Kansas City Heart Rhythm Institute
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: